Pase II study of neoadjuvant chemotherapy with Docetaxel, Carboplatin, and Trastuzumab for operable Her2-positive breast cancer patients.
Phase 2
- Conditions
- Her2-positive breast cancer
- Registration Number
- JPRN-UMIN000012256
- Lead Sponsor
- Kyushu Breast Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Clinically inadequate heart function at the registration and/or with past history. 2.Severe uncontrolled complications (Uncontrolled DM, HT, liver dysfunction, renal dysfunction, infection mental manifestation). 3.Women during pregnancy or shortly after childbirth. 4.Double active cancer (in less than 5 years after the last treatment). 5.Women with bilateral breast cancer (synchronous or heterochronous). 6.Women with pulmonary fibrosis and/or interstitial pneumonia. 7.Patients with allergy to the medicines in this protocol treatment. 8.Patients judged inappropriate for this study by the physicians.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method